Adagene vs Adlai Nortye
ADAG and ANL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADAG and ANL compare
Adagene keeps more of each dollar of sales as profit, with a net margin of −230% compared with −711% at Adlai Nortye.
Adagene scores higher on the StockData Score (5 against 0 for Adlai Nortye), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADAG | ANL |
|---|---|---|
| Size and price | ||
| Share price | $1.60 | $10.03 |
| Change, 1 year | −11.1% | 564% |
| Change, 5 years | −81.6% | – |
| Beta (5Y) | 0.61 | 3.83 |
| Employees | 128 | – |
| StockData Score | ||
| Total score | 5 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 7333% | – |
| Revenue growth, 5Y average | 61.4% | – |
| Profitability | ||
| Operating margin | −279% (better) | −714% |
| Net margin | −230% (better) | −711% |
| FCF margin | −204% (better) | −673% |
| Return on equity | −27.7% | – |
| Financial health | ||
| Debt / equity | 0.06 | – |
| Interest coverage | −46.3× | −23.3× (better) |
| Current ratio | 5.02 (better) | 0.65 |
| Piotroski F-score | 4 (better) | 1 |
| Ownership | ||
| Held by institutions | 32.5% | 22.1% |
| Held by insiders | 16.8% | 14.7% |
| Insider net buying, 12 months | $162K (better) | −$411K |
Go deeper
- ADAG stock overview
- ADAG income statement
- ADAG valuation and score
- ANL stock overview
- ANL income statement
- ANL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.